Cantor Fitzgerald Forecasts TARA FY2026 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Protara Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($1.45) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.18.

Several other research firms also recently commented on TARA. Jones Trading raised Protara Therapeutics to a “strong-buy” rating and set a $21.00 price objective on the stock in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday, April 28th. Lifesci Capital began coverage on Protara Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price objective on the stock. Finally, Scotiabank began coverage on Protara Therapeutics in a research note on Wednesday, April 16th. They issued a “sector outperform” rating and a $12.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $20.50.

Protara Therapeutics Stock Up 3.1%

NASDAQ TARA opened at $3.37 on Tuesday. The stock’s 50-day moving average price is $3.53 and its 200-day moving average price is $4.22. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48. The company has a market capitalization of $130.02 million, a P/E ratio of -1.20 and a beta of 1.34.

Institutional Trading of Protara Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TARA. Oppenheimer & Co. Inc. raised its stake in Protara Therapeutics by 12.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company’s stock valued at $1,064,000 after purchasing an additional 22,301 shares during the period. Bailard Inc. purchased a new position in Protara Therapeutics during the 4th quarter valued at approximately $157,000. Commonwealth Equity Services LLC grew its holdings in Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock valued at $195,000 after buying an additional 17,572 shares in the last quarter. Geode Capital Management LLC grew its holdings in Protara Therapeutics by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company’s stock valued at $948,000 after buying an additional 9,553 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in Protara Therapeutics during the 4th quarter valued at approximately $648,000. Institutional investors own 38.13% of the company’s stock.

Insider Activity at Protara Therapeutics

In related news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the sale, the insider now owns 98,861 shares of the company’s stock, valued at approximately $447,840.33. This trade represents a 17.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.40% of the stock is owned by corporate insiders.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.